Patent details

92249 Product Name: avanafil

Basic Information

Publication number:
92249
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP009609793
Legal Status:
Expired
Application number:
92249
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/13/841 - avanafil
Marketing Authorization Type:
Marketing Authorization Date:
25/06/2013
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
10/07/2013
First Marketing Authorization date:
25/06/2013
Grant date:
10/09/2013
Activation date:
13/09/2020
Publication date:
10/09/2013
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
13/09/2025
SPC Extension Expiration:
13/09/2025
Rejection date:
Withdrawal date:

Owner

From:
10/07/2013
 
 

Name:
MITSUBISHI TANABE PHARMA CORPORATION
Address:
2-6-18, KITAHAMA, CHUO-KU, OSAKA-SHI, OSAKA 541-8505, Japan (JP)

Agent

Name:
DENNEMEYER & ASSOCIATES S.A. PATENT DEPARTMENT
From:
10/07/2013
Address:
PO Box 1502, 1015, LUXEMBOURG, Luxembourg (LU)
To:

Inventor

1

Name:
MATSUKI Kenji
Address:
Japan (JP)

2

Name:
OMORI Kenji
Address:
Japan (JP)

3

Name:
YAMADA Koichiro
Address:
Japan (JP)

4

Name:
KIKKAWA Kohei
Address:
Japan (JP)

Publication

Bulletin

1

Bulletin Heading:
SPC4
Bulletin edition number:
2019/02
Publication date:
22/02/2019
Description:
Section F : Correction of granted supplementary protection certificates – I9 publication

2

Bulletin Heading:
SPC3
Bulletin edition number:
2020/11
Publication date:
02/10/2020
Description:
Section E : Supplementary Protection certificates entered into force – IA publication

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
29/08/2024
Last Annual Fee Paid Number:
25
Last Annual Fee Paid Amount:
450 Euro
Payer:
CPA GLOBAL THE IP PLATFORM
Filing date Document type Number of pages
03/01/2019 Publication 1
03/01/2019 Outgoing Correspondence 1
16/11/2015 Incoming Correspondence (Post) 2